An orally disintegrating tablet comprising Cannabis sativa L. extracts which are substantially free of tetrahydrocannabinol (THC), wherein the extracts have an average diameter of less than 1 micrometer.

The present disclosure is directed to oral tablet of ribociclib including its salt(s). One embodiment of the present disclosure is directed to tablet of ribociclib with high drug load with an immediate release profile. One embodiment of the present disclosure is directed to coated tablet of ribociclib. Another embodiment of the present disclosure is directed to coated tablet of ribociclib where the coating is an advanced moisture barrier coating (e.g., Opadry amb II coating where the coating is PVA based).

The present disclosure provides a stable solid pharmaceutical dosage form for oral administration. The dosage form includes a substrate that forms at least one compartment and a drug content loaded into the compartment. The dosage form is so designed that the active pharmaceutical ingredient of the drug content is released in a controlled manner.

Pharmaceutical compositions for oral administration, in particular administration as an oral delivery system to be swallowed directly or capable of disintegration in the oral cavity, comprising iron oxy-hydroxide in high loading.

Pharmaceutical compositions for oral administration, in particular administration as an oral delivery system to be swallowed directly or capable of disintegration in the oral cavity, comprising iron oxy-hydroxide in high loading.

A powdered composition is disclosed, the powdered composition comprising a complex between one or more cannabinoids having at least one phenolic moiety and a basic ion exchange resin. Also, an orally dispensable delivery vehicle, a method of manufacturing the powdered composition, a method of manufacturing the orally dispensable delivery vehicle, composition for use as a medicament, composition for use in a treatment, method of treatment, and use of a basic ion exchange resin as a stabilizing agent are disclosed.

The present invention relates to a tablet comprising one or more omega-3 fatty acid amino acid salt(s), a method for preparing a tablet according to the invention and the use of a tablet according to the invention as a food supplement or as a pharmaceutical product.

The present application relates to pharmaceutical formulations and dosage forms of a lysine specific demethylase-1 (LSD1) inhibitor, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, including methods of preparation thereof, which are useful in the treatment of LSD1 mediated diseases such as cancer.

The present disclosure relates to formulations, such as tablets, of FXR agonists and therapeutic uses thereof. The disclosure also relates to methods for obtaining such formulations.

The present disclosure relates to an oral, extended release pill containing a drug which is homogenously spread throughout a matrix. The pill can be prepared using a hot melt extrusion process and a forming unit. The formed pill meets regulatory guidelines for extended release formulations and can be abuse deterrent to parenteral administration due at least to particle size, viscosity, or purity limitations.